Aceminib a new option for treating chronic myelogenous leukemia

Asciminib, also known asAsciminib, is an innovative tyrosine kinase inhibitor (TKI) designed for patients with chronic myelogenous leukemia (CML). CML is a rare blood cancer caused mainly by the overexpression of BCR-ABL fusion protein caused by chromosomal abnormalities. This abnormal protein drives the malignant proliferation of leukemia cells. The advent of acemini brings new hope to CML patients who are resistant to traditional treatments.

Aximinib is particularly suitable for patients with CML in the chronic and accelerated phases, especially those who have failed to respond to first- and second-generation TKIs (imatinib, dasatinib, nilotinib, etc.). Aceminib has shown excellent efficacy in the face of a major problem in the treatment of CML - the BCR-ABL T315I mutation. Traditional TKI are often unable to deal with such mutations, but Aceminib, with its unique targeting mechanism, can effectively inhibit the growth of these mutant CML cells.

Aximinib precisely targets the myristoyl binding pocket of the BCR-ABL fusion protein and inhibits the kinase activity of the protein, thereby slowing down the proliferation rate of CML cells. Its unique design enables Asiminib to still exert excellent therapeutic effects in the face of various mutations in BCR-ABL, especially drug-resistant mutations. This innovative mechanism provides patients with more treatment options, especially when other TKI treatments have failed.

Clinical trial results show that aximini can significantly improve the response rate of CML patients, including cytological response (CCR) and molecular response (MR). Patients treated with Asiminib have shown good prognosis in terms of disease control and survival. Especially for patients who have failed other TKI treatments, Asiminib is undoubtedly a new good news.